MilliporeSigma and bluebird bio ink multi-year viral vector deal

By Flora Southey contact

- Last updated on GMT

GettyImages/AntonioGuillem
GettyImages/AntonioGuillem

Related tags: Viral vector, Dna, Gene therapy

Bluebird Bio has hired MilliporeSigma to supply lentiviral vectors for the development of gene therapies.

Under the commercial supply agreement, MilliporeSigma – the life science branch of Merck KGaA – will manufacture vectors for the Massachusetts, US-headquartered firm’s drug products, indicated to treat rare genetic diseases.

Merck told us the lentivrial vectors – which are used to deliver personalised gene therapies into immune cells – will be manufactured at its Carlsbad, California facility.

The firm recently expanded​ the gene therapy facility, which houses viral bulk manufacturing cleanrooms, fill/finish suites and viral vaccine and immunotherapy products.

Merck has expertise in the production of a wide variety of viral vectors used for gene therapy and viral vaccines, the spokesperson told us.

The firm “has a focus on quality in clinical and commercial supply as evidenced by our facility completing both a US Food and Drug Administration[FDA] Pre-License inspection and a European Medicines Agency [EMA] Marketing Authorization inspection,” ​he added.

Outsourcing relationships

A Merck spokesperson told us the firm has worked with bluebird bio “for some time on production of lentiviral vectors across all their programmes.”

In November last year, bluebird bio reaffirmed​ its commitment to its outsourcing partners, when it announced plans to buy a manufacturing facility in North Carolina but continue to work with contract manufacturers.

At the time, bluebird bio said the in-house lentiviral vector manufacturing facility would not disrupt multi-year contracts with firms including Brammer Bio, Novasep, and MilliporeSigma.  

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars